- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oncopeptides AB (ONCO)
Oncopeptides AB stock price live, this page displays ST ONCO stock exchange data. View the ONCO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Oncopeptides AB real time stock price chart below.
What Is the Oncopeptides AB Stock Price Today?
The Oncopeptides AB stock price today is 5.350.
What Is the Stock Symbol for Oncopeptides AB?
The stock symbol for Oncopeptides AB is ""ONCO.""
What Stock Exchange Does Oncopeptides AB Trade On?
Oncopeptides AB is listed and trades on the Stockholm stock exchange.
Is Oncopeptides AB a Good Stock to Buy?
Determining whether Oncopeptides AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ONCO quote. (ISIN: SE0009414576)
What Is the Oncopeptides AB Stock Price Today?
The Oncopeptides AB stock price today is 5.350.
What Is the Stock Symbol for Oncopeptides AB?
The stock symbol for Oncopeptides AB is ""ONCO.""
What Stock Exchange Does Oncopeptides AB Trade On?
Oncopeptides AB is listed and trades on the Stockholm stock exchange.
Is Oncopeptides AB a Good Stock to Buy?
Determining whether Oncopeptides AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ONCO quote. (ISIN: SE0009414576)
Stockholm
Currency in SEK
5.350
+0.110(+2.10%)
Closed·
Fair Value
An estimate of a Oncopeptides's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.130
5.390
52 wk Range
1.100
6.960
ONCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Oncopeptides's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.1305.390
52 wk Range
1.1006.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ONCO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Oncopeptides's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
5.250
Downside
-1.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Enzymatica appoints Holger Lembrér as new CFO
- Investing.com
- Enzymatica appoints Holger Lembrér as new CFO
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Oncopeptides AB Company Profile
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Oncopeptides AB Earnings Call Summary for Q3/2025
- Oncopeptides reported a 174% YoY increase in Q3 2025 net sales to SEK 20.2M, despite a 12.44% stock drop in pre-market trading following the announcement.
- Gross profit reached SEK 19.9M with a 99% margin, while operating expenses decreased by 3% YoY, improving EBIT from -SEK 61.3M to -SEK 47.1M.
- The company strengthened its cash position to SEK 147.9M following a successful rights issue and expanded its European commercial presence with market access in Spain and Italy.
- CEO Sofia Heigis confirmed Oncopeptides is targeting profitability by end-2026, citing 'four consecutive quarters of growth' and 'disciplined cost management.'
- Future strategy includes expanding European market presence, exploring Japanese market entry, and continuing development of its Spike platform with NK cell engagement technology.
Last Updated: 05/11/2025, 09:50
Read Full TranscriptCompare ONCO to Peers and Sector
Metrics to compare | ONCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.7x | 2.8x | −0.6x | |
PEG Ratio | −0.13 | 0.39 | 0.00 | |
Price/Book | 231.6x | 13.7x | 2.6x | |
Price / LTM Sales | 24.2x | 12.1x | 3.3x | |
Upside (Analyst Target) | −0.9% | 57.7% | 41.2% | |
Fair Value Upside | Unlock | 7.2% | 4.8% | Unlock |
Analyst Ratings
0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 5.250
(-1.87% Downside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
-0.27 / --
Revenue / Forecast
20.00M / 32.00M
People Also Watch
FAQ
What Stock Exchange Does Oncopeptides Trade On?
Oncopeptides is listed and trades on the Stockholm Stock Exchange stock exchange.
What Is the Stock Symbol for Oncopeptides?
The stock symbol for Oncopeptides is "ONCO."
What Is the Oncopeptides Market Cap?
As of today, Oncopeptides market cap is 1.46B.
What Is Oncopeptides's Earnings Per Share (TTM)?
The Oncopeptides EPS (TTM) is -1.24.
When Is the Next Oncopeptides Earnings Date?
Oncopeptides will release its next earnings report on 18 Feb 2026.
From a Technical Analysis Perspective, Is ONCO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Oncopeptides Stock Split?
Oncopeptides has split 0 times.
How Many Employees Does Oncopeptides Have?
Oncopeptides has 75 employees.
What is the current trading status of Oncopeptides (ONCO)?
As of 25 Nov 2025, Oncopeptides (ONCO) is trading at a price of 5.350, with a previous close of 5.240. The stock has fluctuated within a day range of 5.130 to 5.390, while its 52-week range spans from 1.100 to 6.960.
What Is Oncopeptides (ONCO) Price Target According to Analysts?
The average 12-month price target for Oncopeptides is SEK5.25, with a high estimate of SEK5.5 and a low estimate of SEK5. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an -1.87% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.